Clinical Trials
8 trialsNCT06613633 2026-04-29
Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC
Fudan University
Completed
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT04965701 2023-11-13
FLOWER
Istituto Oncologico Veneto IRCCS
Completed
NCT04179890 2023-05-25
UpSwinG
Boehringer Ingelheim
Completed
NCT03790397 2022-06-03
OSIREX
Fundación GECP
Completed
NCT03219970 2021-09-14
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
AstraZeneca
Completed
NCT03370770 2020-12-24
Afatinib Osimertinib Sequencing NIS
Boehringer Ingelheim
Completed
NCT03133234 2018-11-20
Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC
AstraZeneca
Completed